Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-001 in children with autism spectrum disorder
NCT06333964Phase 3Completed
- Sponsor
- Astrogen
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing AST-001 with Placebo → AST-001 (2 arms). Primary endpoint: Korean-Vineland Adaptive Behavior Scale-II at 24 weeks. Started Aug 2023; status: completed.
02
Drugs
Threonine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06333964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333964.